Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Canaan (CAN) Research & Development (2018 - 2025)

Canaan has reported Research & Development over the past 8 years, most recently at -$11.5 million for Q4 2025.

  • Quarterly Research & Development rose 30.87% to -$11.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$63.1 million through Dec 2025, down 2.97% year-over-year, with the annual reading at $63.1 million for FY2025, 2.97% up from the prior year.
  • Research & Development was -$11.5 million for Q4 2025 at Canaan, up from -$16.3 million in the prior quarter.
  • Over five years, Research & Development peaked at -$8.9 million in Q1 2021 and troughed at -$33.4 million in Q4 2022.
  • The 5-year median for Research & Development is -$16.0 million (2022), against an average of -$16.1 million.
  • Year-over-year, Research & Development plummeted 210.26% in 2021 and then skyrocketed 67.7% in 2023.
  • A 5-year view of Research & Development shows it stood at -$17.6 million in 2021, then crashed by 89.81% to -$33.4 million in 2022, then skyrocketed by 67.7% to -$10.8 million in 2023, then plummeted by 53.76% to -$16.6 million in 2024, then soared by 30.87% to -$11.5 million in 2025.
  • Per Business Quant, the three most recent readings for CAN's Research & Development are -$11.5 million (Q4 2025), -$16.3 million (Q3 2025), and -$16.4 million (Q2 2025).